Sangamo Therapeutics (SGMOQ) Cash & Equivalents (2010 - 2025)

Sangamo Therapeutics has reported Cash & Equivalents for 16 years, with the latest figure at $20.9 million in Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 50.03% year-over-year to $20.9 million in Q4 2025; TTM through Dec 2025 was $20.9 million, a 50.03% decrease from a year earlier, with the FY2025 full-year figure at $20.9 million, down 50.03% from the prior year.
• Cash & Equivalents was $20.9 million for Q4 2025 at Sangamo Therapeutics, down from $29.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $178.9 million in Q4 2021, with the low at $20.9 million in Q4 2025.
• Average Cash & Equivalents over 5 years is $80.3 million, with a median of $61.7 million recorded in 2023.
• The largest YoY upside for Cash & Equivalents was 43.41% in 2021 against a maximum downside of 63.66% in 2021.
• Over 5 years, Cash & Equivalents stood at $178.9 million in 2021, then tumbled by 43.85% to $100.4 million in 2022, then plunged by 55.0% to $45.2 million in 2023, then fell by 7.27% to $41.9 million in 2024, then sank by 50.03% to $20.9 million in 2025.
• The last three Cash & Equivalents figures came in at $20.9 million (Q4 2025), $29.6 million (Q3 2025), and $38.3 million (Q2 2025), per Business Quant data.